目的 探討慢性盆腔炎采用婦炎康丸與克林霉素聯(lián)合治療的臨床療效。方法 納入2023年6月—2024年6月在三二〇一醫(yī)院就診的120例慢性盆腔炎患者，按隨機數(shù)字表法分為對照組（n=60）和治療組（n=60）。對照組患者口服克林霉素磷酸酯片，0.3 g/次，3次/d。治療組患者口服婦炎康丸，5 g/次，2次/d。兩組均以4周為1個療程，連續(xù)治療3個療程。對比并分析兩組患者臨床治療效果、盆腔炎性包塊直徑、盆腔積液深度、血清炎癥因子、臨床癥狀消失時間。結(jié)果 治療后，治療組總有效率明顯高于對照組（93.33% vs 80.00%，P＜0.05）。治療后，兩組盆腔炎性包塊直徑和盆腔積液深度均明顯小于治療前（P＜0.05），且治療組患者盆腔炎性包塊直徑和盆腔積液深度明顯小于對照組（P＜0.05）。治療后，兩組血清白細胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）和C反應(yīng)蛋白（CRP）水平均低于治療前（P＜0.05），且治療組患者血清IL-6、TNF-α、CRP水平明顯低于對照組（P＜0.05）。治療后，治療組下腹部疼痛消失時間、墜脹消失時間、腰骶部酸痛消失時間以及白帶增多消失時間均短于對照組（P＜0.05）。結(jié)論 婦炎康丸聯(lián)合克林霉素治療慢性盆腔炎能夠提升臨床療效，減小盆腔炎性包塊直徑和盆腔積液深度，降低血清炎癥因子水平。

Objective To explore the clinical efficacy of the combined treatment of Fuyankang Pills and clindamycin for chronic pelvic inflammatory disease. Methods A total of 120 patients with chronic pelvic inflammatory disease who visited 3201 Hospital from June 2023 to June 2024 were included and divided into the control group (n=60) and the treatment group (n=60) according to the random number table method. Patients in control group were po administered with Clindamycin Phosphate Tablets, 0.3 g each time, three times daily. Patients in treatment group took Fuyankang Pills orally, 5 g each time, twice daily. Both groups were treated with 4 weeks as one course of treatment for 3 consecutive courses. Both groups of patients took 4 weeks as one course of treatment and continued the treatment for 3 courses. The clinical therapeutic effects, diameters of pelvic inflammatory masses, depth of pelvic effusion, serum inflammatory factors, and disappearance time of clinical symptoms of the two groups of patients were compared and analyzed. Results After treatment, the total effective rate of the treatment group was significantly higher than that of the control group (93.33% vs 80.00%, P < 0.05). After treatment, the diameters of pelvic inflammatory masses and the depth of pelvic effusion in both groups were significantly smaller than those before treatment (P < 0.05), and diameters of pelvic inflammatory masses and the depth of pelvic effusion in the treatment group were significantly smaller than those in the control group (P < 0.05). After treatment, the levels of serum IL-6, TNF-α, and CRP in both groups were lower than those before treatment (P < 0.05), and the levels of serum factors in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the relief time for lower abdominal pain, distension, lumbosacral soreness and increased vaginal discharge in the treatment group was shorter than that in the control group (P < 0.05). Conclusion The combined treatment of Fuyankang Pills and clindamycin for chronic pelvic inflammatory disease can improve the curative effect, reduce the diameter of pelvic inflammatory masses and the depth of pelvic effusion, lower the levels of serum inflammatory factors.

R984

陜西省衛(wèi)生健康科研基金資助項目（2024D025）